<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Five patients with confirmed Fanconi's <z:hpo ids='HP_0001903'>anemia</z:hpo> (FA) and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and/or <z:hpo ids='HP_0001909'>leukemia</z:hpo> underwent stem cell transplantation (SCT) from related donors at KFSHRC </plain></SENT>
<SENT sid="1" pm="."><plain>The median age at SCT was 12.6 year (range, 6.2-15 years) </plain></SENT>
<SENT sid="2" pm="."><plain>Conditioning regimen consisted of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) 5 mg/kg/day i.v. for 4 days, total body irradiation (TBI) 450 cGy in a single dose </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis was with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and antithymocyte globulins (ATG) </plain></SENT>
<SENT sid="4" pm="."><plain>The median time to engraftment (defined as ANC&gt;/=0.5 x 10(9)/l) was 16 days (range, 12-26 days) </plain></SENT>
<SENT sid="5" pm="."><plain>The median time to a self-sustaining platelet count of &gt;/=20 x 10(9)/l was 27 days (range, 12-40 days) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients engrafted </plain></SENT>
<SENT sid="7" pm="."><plain>Two patients developed <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD; one of the gut (grade 3) and the other of the skin (grade 1), and one patient developed <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD of the liver </plain></SENT>
<SENT sid="8" pm="."><plain>Four are alive and well with no evidence of the disease; one patient died of <z:mp ids='MP_0001794'>bacterial</z:mp> <z:hpo ids='HP_0100806'>sepsis</z:hpo> after controlling her GVHD and clearing her <z:e sem="disease" ids="C0004031" disease_type="Disease or Syndrome" abbrv="">pulmonary aspergillosis</z:e> and <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that the use of low-dose CY plus TBI in patients with FA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> undergoing SCT is adequate; the regimen is well tolerated and may be curative for such patients </plain></SENT>
</text></document>